Bharat Biotech: News

COVAXIN trial data for children aged 2-18 submitted to DCGI

Bharat Biotech has reportedly submitted trial data of its COVID-19 vaccine, COVAXIN, for children aged under 18 years to the Drugs and Comptroller General of India (DCGI).

Decision on EUL of COVAXIN in October, says WHO

A decision on Bharat Biotech's submission seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN will be made in October, the World Health Organization has said.

21 Sep 2021


COVAXIN for children: Bharat Biotech completes Phase 2/3 trials

Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, COVAXIN for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman, and Managing Director of Bharat Biotech International Ltd., Krishna Ella said.

Bharat Biotech awaits feedback from WHO for COVAXIN's EUL

Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine COVAXIN to the World Health Organization for EUL and is awaiting feedback from the global health watchdog.

Single COVAXIN dose might be enough for those previously infected

A single dose of Bharat Biotech's COVAXIN in previously COVID-19-infected individuals elicits a similar antibody response as obtained with two doses of the vaccine in those without a previous history of the disease, according to an ICMR study.

24 Jul 2021


Bharat Biotech ends its Brazil agreement. What went wrong?

Bharat Biotech on Friday announced the termination its agreement with two foreign firms for the supply of COVAXIN to Brazil.

23 Jul 2021


Bharat Biotech commits to supply 500mn COVAXIN doses to Centre

Bharat Biotech on Friday said it has committed to supply over 500 million doses of COVAXIN to the Centre under the countrywide immunization program.

28 May 2021

COVID-19 Vaccine

Bharat Biotech enters contract manufacturing deal for COVAXIN drug substance

Hester Biosciences on Thursday said a memorandum of understanding (MoU) has been signed between Hyderabad-based vaccine maker Bharat Biotech and Gujarat COVID-19 Vaccine Consortium (GCVC) for contract manufacturing the drug substance for COVAXIN.

03 Jul 2021


COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech

COVAXIN, the coronavirus vaccine developed by India's Bharat Biotech, is overall 77.8 percent effective, the company said in a statement today, sharing the final analysis of its phase three trial data.

30 Jun 2021


Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil

Hyderabad-based pharmaceutical company Bharat Biotech denied any wrongdoing on its part after Brazil suspended a $324 million contract for doses of its COVID-19 vaccine COVAXIN.

22 Jun 2021


COVAXIN 77.8% effective; government panel reviews Phase III trial data

COVAXIN, the COVID-19 vaccine developed by Bharat Biotech, has been found 77.8% effective against the viral disease, Phase III trial data reportedly revealed.

16 Jun 2021


Calf serum absent in COVAXIN, involved in development, government clarifies

COVAXIN, the indigenous COVID-19 vaccine produced by Bharat Biotech, does not contain calf serum, the Union Health Ministry clarified on Wednesday.

AIIMS-Delhi begins screening children for COVAXIN clinical trials from today

The All India Institute of Medical Sciences (AIIMS), Delhi will begin screening children from Monday to conduct clinical trials of the indigenously developed, Bharat Biotech's vaccine against COVID-19, COVAXIN.

Health Ministry thrashes reports about 'missing' COVAXIN doses

The Health Ministry has slammed news about unaccounted COVAXIN doses as "unfound media reports" adding that these reports are incorrect and not supported by full information on the matter.

28 May 2021

Aam Aadmi Party (AAP)

Centre creating 'artificial scarcity' of COVID-19 vaccines: AAP

The AAP on Friday alleged that the Centre is creating artificial scarcity of COVID-19 vaccines to benefit Bharat Biotech and Serum Institute of India, a charge termed by the Delhi BJP as unfounded.

Need more information to give EUL to COVAXIN: WHO

The World Health Organization (WHO) has said that more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN.

COVAXIN trials on children are expected to begin in June

Bharat Biotech, the pharmaceutical firm behind India's first indigenous COVID-19 vaccine COVAXIN, may begin trials on children in June and is expecting to receive the license in the third quarter of this year.

21 May 2021


Bharat Biotech to increase COVAXIN production by 200 million doses

Hyderabad-based firm Bharat Biotech has said it will scale up the manufacturing capacity of its coronavirus vaccine, COVAXIN, by an additional 200 million (20 crore) doses per year.

13 May 2021


COVAXIN approved for Phase 2/3 trials on 2-18-year-olds

India's apex drug regulator has granted permission for conducting the Phase II/III clinical trial of Bharat Biotech's COVAXIN in the age group of 2 to 18 years, the Union Health Ministry said on Thursday. The trial will be conducted on 525 healthy volunteers.

12 May 2021


Government-owned BIBCOL to produce 2 crore COVAXIN doses every month

To accelerate the production of COVAXIN—the indigenous COVID-19 vaccine developed by Hyderabad-based Bharat Biotech—amid severe vaccine shortage in India, the Centre on Wednesday reportedly gave its nod for production of COVAXIN at government-owned Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) in Uttar Pradesh's Bulandshahr.

12 May 2021


COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel

In a bid to extend the country's vaccination drive to include people below 18 years, an expert panel on Tuesday recommended Hyderabad-based Bharat Biotech's COVID-19 vaccine COVAXIN for phase 2/3 clinical trials on children and adolescents aged two to 18 years.

01 May 2021

Madhya Pradesh

Truck laden with COVAXIN abandoned for 12 hours, driver missing

A truck carrying 2.40 lakh doses of COVAXIN worth Rs. 8 crore was left parked for nearly 12 hours after its driver went missing under mysterious circumstances in Madhya Pradesh's Narsinghpur district.

29 Apr 2021


Bharat Biotech reduces COVAXIN price to Rs. 400 for states

Hyderabad-based pharmaceutical company Bharat Biotech on Thursday reduced the price of its COVID-19 vaccine, COVAXIN, for state governments.

20 Apr 2021


Bharat Biotech to produce 700 million COVAXIN doses per year

To support vaccination campaigns in India and across the globe, Bharat Biotech has ramped up the manufacturing capacity of its COVID-19 vaccine, COVAXIN, to 700 million doses per annum, the vaccine maker said on Tuesday.

31 Mar 2021


COVAXIN manufacturing facility fails to meet CGMP standards: Brazilian regulator

The Brazilian health regulator Anvisa denied permission to import Bharat Biotech's COVID-19 vaccine COVAXIN into the country after its authorities found that the plant in which the vaccine is being made did not meet the Current Good Manufacturing Practice requirements.

20 Mar 2021


Nepal gives emergency use approval to Bharat Biotech's COVAXIN

Nepal's national drug regulatory authority on Saturday granted emergency use approval to Bharat Biotech's COVAXIN, becoming the third country to approve India's indigenously developed COVID-19 vaccine.

09 Mar 2021


COVAXIN Phase-II trial interim data shows better reactogenicity, safety: Lancet

COVAXIN, the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech, has shown better reactogenicity and safety, Phase II trial interim data published in The Lancet journal showed.

04 Mar 2021

Delhi High Court

Delhi HC pulls up Centre for exporting COVID-19 vaccines

The Delhi High Court on Thursday pulled up the central government over restricted COVID-19 vaccinations in India, even as vaccine exports to other nations continue.

03 Mar 2021


COVAXIN 81% effective, offers protection against UK variant: Bharat Biotech

COVAXIN, the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech, has been found to have 81% interim efficacy against preventing infections, the company said on Wednesday.

27 Jan 2021


COVAXIN may neutralize UK strain of COVID-19: Review report

COVAXIN, developed by Bharat Biotech, has the ability to neutralize the UK variant of the coronavirus, according to a pre-print review by bioRxiv, a free online archive and distribution service for unpublished pre-prints in the life sciences.

24 Jan 2021


Coronavirus: Nearly 16 lakh vaccinated in India as pace accelerates

As the first phase of COVID-19 vaccinations is underway in India, nearly 16 lakh healthcare and frontline workers have been inoculated, government data showed.

Panel recommends permission for Phase I Intranasal COVID-19 vaccine trial

An expert panel, Central Drugs Standard Control Organisation, (CDSCO) on Tuesday recommended granting permission for conducting the Phase I clinical trial of an intranasal vaccine against COVID-19 developed by Bharat Biotech, official sources said.

19 Jan 2021


Centre issues a new Letter of Comfort to Bharat Biotech

Bharat Biotech secured a fresh Letter of Comfort from the Centre for 45 lakh doses of its COVID-19 vaccine, COVAXIN.

19 Jan 2021


Who shouldn't take COVAXIN? Maker Bharat Biotech issues fact-sheet

Two days after India started its coronavirus vaccination program, Hyderabad-based Bharat Biotech released guidelines revealing who should receive shots of COVAXIN.

17 Jan 2021

Madhya Pradesh

Co-WIN app suffers glitches on 1st day of vaccination drive

The COVID-19 Vaccine Intelligence Network (Co-WIN) platform suffered several glitches on the first day of India's vaccination drive.

17 Jan 2021


Meet India's frontline workers who received first COVID-19 vaccine shots

On Saturday, India launched its COVID-19 vaccination drive, inoculating 1.91 lakh people on the first day alone.

13 Jan 2021


COVAXIN shipped to eleven cities in India: Bharat Biotech

Bharat Biotech, on Wednesday, said that it has successfully air-shipped its COVID-19 vaccine COVAXIN to eleven cities in India in the early hours. It has also donated 16.5 lakh doses to the Centre.

11 Jan 2021

Narendra Modi

Centre will sponsor vaccination of healthcare, frontline workers: PM Modi

In his first interaction with chief ministers of all states after India approved two vaccines, Prime Minister Narendra Modi said the federal government will sponsor the vaccination of three crore healthcare and frontline workers.

09 Jan 2021

Madhya Pradesh

Days after participating in vaccine trial, man dies in Bhopal

A 42-year-old volunteer named Deepak Marawi, from Bhopal in Madhya Pradesh died nearly ten days after he participated in the clinical trial for COVAXIN held at a private hospital, its vice-chancellor said on Saturday.

08 Jan 2021

Oxford University

Severe side-effects after COVID-19 vaccine: What are your legal options?

India is looking forward to launching a massive COVID-19 vaccination drive with two vaccines that have been granted emergency use authorization (EUA).